Tumor glucose consumption is well-known to metabolically restrict T cells, impairing their cytotoxic functions and accelerating tumor progression.29–33 We assessed the impact of SRSF1 on glycolytic metabolism by measuring glycolytic capacity with a Seahorse instrument. The gene discussed is SRSF1; the disease is neoplasm.